The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is: • Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.
Study Type
OBSERVATIONAL
Enrollment
210
For AML patients with MLL rearrangement enrolled, leukemia stem cell will be detcted at diagnosis and during follow-up. A traditional Minimal residual disease was deteced as normal medical care, simultaneously, leukemia stem cell will be detcted using the sample bone marrow sample.
Peking University People's Hospital
Beijing, China
RECRUITINGRelapse
Relapse was defined by the morphological evidence of disease in the peripheral blood, BM or extramedullary sites
Time frame: Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.
leukemia-free survival
Leukemia-free survival was defined as survival in continuous complete remission.
Time frame: Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.
overall survival
Overall survival referred to patients who survived until the final follow-up time point
Time frame: Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.